Actively Recruiting

Age: 0 - 100Years
All Genders
ID00669266

Investigation of the Tumorigenesis of Adrenal Tumors and Evaluation of New Therapeutic Options

Led by University of Wuerzburg · Updated on 2026-05-07

500

Participants Needed

1

Research Sites

104 weeks

Total Duration

On this page

Sponsors

U

University of Wuerzburg

Lead Sponsor

D

Deutsche Krebshilfe e.V., Bonn (Germany)

Collaborating Sponsor

AI-Summary

What this Trial Is About

Researchers are investigating the causes and development of adrenal tumors, which include adrenocortical carcinoma, Cushing syndrome, Conn syndrome, and pheochromocytoma. The study aims to better understand how these tumors form and to evaluate new treatment options for patients with malignant adrenal tumors, addressing the limited current therapies available. This observational research is sponsored by the University of Wuerzburg and has been ongoing since 2002. Participants in the study may provide tumor material and related biological samples if they have adrenal tumors. Additionally, biological samples are collected from patients without adrenal tumors to serve as comparison controls. The research does not involve experimental treatments but focuses on collecting and analyzing biospecimens to explore tumor biology and potential therapies. Throughout the study, participants contribute by providing tumor and biosample materials. Researchers analyze these samples to study tumor characteristics and evaluate possible new treatments. There are no specific outcome measures listed. The study is observational, with no assigned treatments, and aims to gather information to support future therapeutic developments. Participants' involvement duration varies, and the study is expected to continue until December 2032.

CONDITIONS

Brief Title

Adrenal Tumors - Pathogenesis and Therapy

Who Can Participate

Age: 0 - 100Years
All Genders

Eligibility Criteria

Eligible

You may qualify if you...

  • Adrenal tumor detected by imaging
Not Eligible

You will not qualify if you...

History of severe allergic reactions to study medication Currently pregnant or breastfeeding Recent participation in another clinical trial within the last 30 days Presence of uncontrolled medical conditions that could affect safety

AI-Screening

AI-Powered Screening

Complete this quick 3-step screening to check your eligibility

1
2
3
+1

Your Study Journey

Screening

Duration - 2 to 4 weeks

Participants are screened for eligibility to participate in the trial.

Sample Collection

Duration - Varies depending on participant enrollment

Participants provide tumor material and biosamples or biomaterial for research purposes based on their group assignment.

Trial Site Locations

Total: 1 location

1

University of Wuerzburg

Würzburg, Germany, 97080

Actively Recruiting

Loading map...

Research Team

M

Martin Fassnacht, MD

How is the study designed?

Study Type

OBSERVATIONAL

Masking

N/A

Allocation

N/A

Model

N/A

Primary Purpose

N/A

Number of Arms

2

Similar Trials

Receptor Radionuclide Therapy With 177Lu-DOTATOC (177Lu-edot...

Neuroendocrine Tumors

Actively Recruiting

2 locations

A Prospective Exploratory Study Evaluating the Diagnostic Us...

Pheochromocytoma

Actively Recruiting

2 locations

A Study of 18F-MFBG Imaging for Tumor Burden and Diagnostic ...

Neuroendocrine Tumor

Actively Recruiting

1 location

Frequently Asked Questions

Have more questions? Get in touch with our team for quick support

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here

Published Research Related To This Trial

FGF/FGFR signaling in adrenocortical development and tumorigenesis: novel potential therapeutic targets in adrenocortical carcinoma.

Mariangela Tamburello, Barbara Altieri, Iuliu Sbiera...

https://pubmed.ncbi.nlm.nih.gov/35583844

Active steroid hormone synthesis renders adrenocortical cells highly susceptible to type II ferroptosis induction.

Isabel Weigand, Jochen Schreiner, Florian Röhrig...

https://pubmed.ncbi.nlm.nih.gov/32184394